ERNA (Ernexa Therapeutics) Moat Score: 2/10 (As of Jul. 04, 2026)


ERNA Ernexa Therapeutics Inc ERNA
30 GF Score
Price $6.45
! 4 Warning Signs
View Full Analysis

What is Ernexa Therapeutics Moat Score?

Ernexa Therapeutics ERNA -6.48% 30 Moat Score is 2 as of Jul. 04, 2026. GuruFocus rates ERNA with a GF Score™ of 30/100. The stock has 4 warning signs investors should review. Among 1,399 Biotechnology companies, Ernexa Therapeutics ranks better than 58.11% on this metric.

Ernexa Therapeutics has the Moat Score of 2, which implies that the company might have No Moat - Very weak/transient advantages.

Ernexa Therapeutics has No Moat: Ernexa Therapeutics Inc is in the early stages of development with no significant intellectual property or market presence. The company lacks brand strength, regulatory barriers, and cost advantages, resulting in a weak competitive position.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Ernexa Therapeutics might have No Moat - Very weak/transient advantages.

Ernexa Therapeutics  (NAS:ERNA) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Ernexa Therapeutics Moat Score Related Terms

ERNA vs PMCB, SYBX, ASBP: Moat Score Comparison

For the Biotechnology subindustry, Ernexa Therapeutics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ernexa Therapeutics Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ernexa Therapeutics's Moat Score distribution charts can be found below:

* The bar in red indicates where Ernexa Therapeutics's Moat Score falls into.


ERNA
30GF Score
Ernexa Therapeutics Inc ERNA
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 2 mean?
Ernexa Therapeutics (ERNA) has a Moat Score of 2 as of Jul. 04, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Ernexa Therapeutics ranks #586 out of 1399 companies in the Biotechnology industry, placing it in the top 41.9%.
Is Ernexa Therapeutics' Moat Score too high?
Ernexa Therapeutics' current Moat Score is 2. The Biotechnology industry median Moat Score is 2.00. Ernexa Therapeutics' value of 2 is 0% at this industry median. Based on the distribution chart, Ernexa Therapeutics ranks #586 out of 1399 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Ernexa Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Ernexa Therapeutics' Moat Score compare to PMCB and SYBX?
According to the Biotechnology industry distribution chart, Ernexa Therapeutics ranks #586 out of 1399 companies for Moat Score. This puts Ernexa Therapeutics in the upper half of its industry. The industry median Moat Score is 2.00. Ernexa Therapeutics' value of 2 is 0% at this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,399 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ernexa Therapeutics's current Moat Score of 2 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ernexa Therapeutics's current Moat Score is 2. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ernexa Therapeutics stock overvalued right now?
Ernexa Therapeutics (ERNA) has a current Moat Score of 2. The current Moat Score is 2 and 0% at the Biotechnology industry median of 2.00. Ernexa Therapeutics' overall GF Score™ is 30/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Ernexa Therapeutics (ERNA), the current Moat Score is 2 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ernexa Therapeutics Business Description

Address 1035 Cambridge Street, Suite 18A, Cambridge, MA, USA, 02141
Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.
30GF Score

Get the complete analysis for ERNA

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.45
Price